First line aromatase inhibitor (AI) plus palbociclib with randomized switch to fulvestrant plus palbociclib upon detection of circulating ESR1 mutation in HR+HER2-metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase III trial
CANCER RESEARCH(2022)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined